86 related articles for article (PubMed ID: 24378998)
21. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of sacral neuromodulation (SNM) with Interstim for fecal incontinence patients in Spain.
Brosa M; Muñoz-Duyos A; Navarro-Luna A; Rodriguez JM; Serrano D; Gisbert R; Dziekan K; Segú JL
Curr Med Res Opin; 2008 Mar; 24(3):907-18. PubMed ID: 18279582
[TBL] [Abstract][Full Text] [Related]
23. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
Pradelli L; Iannazzo S; Zaniolo O
Am J Cardiovasc Drugs; 2009; 9(6):383-92. PubMed ID: 19929036
[TBL] [Abstract][Full Text] [Related]
24. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure.
Long EF; Swain GW; Mangi AA
Circ Heart Fail; 2014 May; 7(3):470-8. PubMed ID: 24563450
[TBL] [Abstract][Full Text] [Related]
25. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of endarterectomy in patients with asymptomatic carotid artery stenosis.
Henriksson M; Lundgren F; Carlsson P
Br J Surg; 2008 Jun; 95(6):714-20. PubMed ID: 18412295
[TBL] [Abstract][Full Text] [Related]
27. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
28. Baroreceptor Stimulation for Resistant Hypertension.
Yoruk A; Bisognano JD; Gassler JP
Am J Hypertens; 2016 Dec; 29(12):1319-1324. PubMed ID: 27444637
[TBL] [Abstract][Full Text] [Related]
29. Safety profile of baroreflex activation therapy (NEO) in patients with resistant hypertension.
Wallbach M; Böhning E; Lehnig LY; Schroer C; Müller GA; Wachter R; Lüders S; Zenker D; Koziolek MJ
J Hypertens; 2018 Aug; 36(8):1762-1769. PubMed ID: 29677053
[TBL] [Abstract][Full Text] [Related]
30. Spinal cord stimulation for failed back surgery syndrome: a decision-analytic model and cost-effectiveness analysis.
Taylor RJ; Taylor RS
Int J Technol Assess Health Care; 2005; 21(3):351-8. PubMed ID: 16110715
[TBL] [Abstract][Full Text] [Related]
31. Barostim Implantation with Ipsilateral Carotid Endarterectomy as a One-Stage Procedure.
Weipert KF; Most A; Doerr O; Koshty A; Hamm CW; Erkapic D; Schmitt J
Ann Vasc Surg; 2016 Oct; 36():295.e9-295.e11. PubMed ID: 27423727
[TBL] [Abstract][Full Text] [Related]
32. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis.
Tomaszewski KJ; Holloway RG
Neurology; 2001 Aug; 57(4):663-71. PubMed ID: 11524476
[TBL] [Abstract][Full Text] [Related]
33. [Baroreflex activation therapy : Indication and evidence in resistant hypertension and heart failure].
Wallbach M; Koziolek MJ; Wachter R
Internist (Berl); 2018 Oct; 59(10):1011-1020. PubMed ID: 30182192
[TBL] [Abstract][Full Text] [Related]
34. [Carotid barostimulation in the treatment of resistant hypertension].
Rossignol P
Nephrol Ther; 2016 Apr; 12 Suppl 1():S133-4. PubMed ID: 26972094
[TBL] [Abstract][Full Text] [Related]
35. [Economic efficiency of renal denervation in patients with resistant hypertension: results of Markov modeling].
Kontsevaia AV; Suvorova EI; Khudiakov MB
Kardiologiia; 2014; 54(1):41-7. PubMed ID: 24881310
[TBL] [Abstract][Full Text] [Related]
36. What price for blood pressure control?
Textor SC
J Clin Hypertens (Greenwich); 2009 Oct; 11(10):537-9. PubMed ID: 19817933
[No Abstract] [Full Text] [Related]
37. Cost-effectiveness analysis of different hypertension management strategies in a community setting.
Zhang X; Liao H; Shi D; Li X; Chen X; He S
Intern Emerg Med; 2020 Mar; 15(2):241-250. PubMed ID: 31321709
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis in the treatment of hypertension: a medical view.
Whitworth J; Lang D; Henry D
Clin Exp Hypertens; 1999; 21(5-6):999-1008. PubMed ID: 10423120
[TBL] [Abstract][Full Text] [Related]
39. Utilities of Patients with Hypertension in Northern Vietnam.
Nguyen TP; Krabbe PF; Nguyen TB; Schuiling-Veninga CC; Wright EP; Postma MJ
PLoS One; 2015; 10(10):e0139560. PubMed ID: 26506444
[TBL] [Abstract][Full Text] [Related]
40. Non-clinical and Pre-clinical Testing to Demonstrate Safety of the Barostim Neo Electrode for Activation of Carotid Baroreceptors in Chronic Human Implants.
Wilks SJ; Hara SA; Ross EK; Nicolai EN; Pignato PA; Cates AW; Ludwig KA
Front Neurosci; 2017; 11():438. PubMed ID: 28824361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
